Regarding “Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients”

被引：0
|
作者：
Hiu-Fung Yuen
Shu-Dong Zhang
Ashley San-Yu Wong
Cian M. McCrudden
Yu-Han Huang
Kelvin Yuen-Kwong Chan
Mohamed El-Tanani
Ui-Soon Khoo
机构：
[1] Queen’s University of Belfast,Center for Cancer Research and Cell Biology
[2] Queen’s University of Belfast,School of Pharmacy
[3] A*STAR,Institute of Molecular and Cell Biology
[4] The University of Hong Kong,Department of Pathology
来源：
Breast Cancer Research and Treatment | 2012年 / 131卷
关键词：
Breast Cancer Patient; Epithelial Mesenchymal Transition; Nuclear Expression; Short Survival Time; Early Breast Cancer Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 352
页数：1
相关论文
共 50 条
  • [21] Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
    Bostner, Josefine
    Alayev, Anya
    Berman, Adi Y.
    Fornander, Tommy
    Nordenskjold, Bo
    Holz, Marina K.
    Stal, Olle
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 17 - 27
  • [22] Pregnancy after a diagnosis of estrogen receptor-positive breast cancer does not affect prognosis
    Barton, Mary Kay
    CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (03) : 143 - 144
  • [23] Estrogen Receptor-Positive Breast Cancer in Japanese Women: Trends in Incidence, Characteristics and Prognosis
    Yamashita, H.
    Iwase, H.
    Toyama, T.
    Takahashi, S.
    Sugiura, H.
    Yoshimoto, N.
    Endo, Y.
    Kobayashi, S.
    CANCER RESEARCH, 2010, 70
  • [24] MiR-187 is a marker of poor prognosis in estrogen receptor-positive breast cancer
    Mulrane, Laoighse
    Madden, Stephen
    Brennan, Donal J.
    Mcgee, Sharon F.
    Jirstrom, Karin
    van't Veer, Laura
    Bernards, Rene
    Higgins, Des
    Gallagher, William M.
    O'Connor, Darran P.
    CANCER RESEARCH, 2010, 70
  • [25] Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
    Josefine Bostner
    Anya Alayev
    Adi Y. Berman
    Tommy Fornander
    Bo Nordenskjöld
    Marina K. Holz
    Olle Stål
    Breast Cancer Research and Treatment, 2018, 168 : 17 - 27
  • [26] Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis
    Yamashita, H.
    Iwase, H.
    Toyama, T.
    Takahashi, S.
    Sugiura, H.
    Yoshimoto, N.
    Endo, Y.
    Fujii, Y.
    Kobayashi, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1318 - 1325
  • [27] Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer
    Lu, Qianyi
    Xia, Wen
    Lee, Kaping
    Zhang, Jingmin
    Yuan, Huimin
    Yuan, Zhongyu
    Shi, Yanxia
    Wang, Shusen
    Xu, Fei
    ONCOLOGIST, 2020, 25 (01): : 21 - +
  • [28] Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer
    Cheung, Yee-Ming
    Ramchand, Sabashini K.
    Yeo, Belinda
    Grossmann, Mathis
    JOURNAL OF THE ENDOCRINE SOCIETY, 2019, 3 (07) : 1283 - 1301
  • [29] Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes
    Yoshida, N
    Omoto, Y
    Inoue, A
    Eguchi, H
    Kobayashi, Y
    Kurosumi, M
    Saji, S
    Suemasu, K
    Okazaki, T
    Nakachi, K
    Fujita, T
    Hayashi, S
    CANCER SCIENCE, 2004, 95 (06) : 496 - 502
  • [30] SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
    Alfarsi, Lutfi H.
    El Ansari, Rokaya
    Craze, Madeleine L.
    Mohammed, Omar J.
    Masisi, Brendah K.
    Ellis, Ian O.
    Rakha, Emad A.
    Green, Andrew R.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 317 - 331
12345